Agmatine augmentation in treatment-resistant obsessive-compulsive disorder: a prospective open-label case series

This case series provides preliminary, early evidence supporting agmatine's safety and potential efficacy as augmentation therapy in treatment-resistant OCD. The gradual response pattern and 40% responder rate warrant controlled trials to definitively establish efficacy and identify predictors of treatment response.